<div id="readability-page-1"><p>Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) have been given a consensus rating of &#34;Moderate Buy&#34; by the five brokerages that are  covering the stock, MarketBeat.com reports. One research analyst  has rated the stock with a sell rating, three have given a buy rating and one  has issued  a strong buy rating on  the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $3.3333.</p><ul><li>November’s Small-Cap Treasures: 3 Stocks Poised for Growth</li></ul><p>CGTX has been the subject of a number of research reports. B. Riley  reiterated a &#34;buy&#34; rating and set a $3.00 price target (up from $2.00) on shares of Cognition Therapeutics in a research report on Friday. Wall Street Zen raised shares of Cognition Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 8th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Cognition Therapeutics in a report on Tuesday. Chardan Capital  reissued a &#34;buy&#34; rating and set a $4.00 price objective on shares of Cognition Therapeutics in a research note on Friday, August 8th. Finally, HC Wainwright  reaffirmed a &#34;buy&#34; rating and issued a $3.00 target price on shares of Cognition Therapeutics in a research note on Wednesday.</p><div><p><span></span><span>Get <strong>Cognition Therapeutics</strong> alerts:</span></p></div><p><b>Check Out Our Latest Stock Analysis on Cognition Therapeutics</b></p><h2>Cognition Therapeutics Stock Up 4.5%</h2><p>CGTX stock traded up $0.06 on Friday, reaching $1.39. 916,768 shares of the company's stock were exchanged, compared to its average volume of 1,075,655. Cognition Therapeutics has a twelve month low of $0.22 and a twelve month high of $3.83. The stock has a fifty day moving average of $1.60 and a 200-day moving average of $1.15. The firm has a market cap of $122.70 million, a PE ratio of -2.90 and a beta of 1.23. </p><p>Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01.  On average, equities research analysts predict that  Cognition Therapeutics will post -0.8 EPS for the current fiscal year. </p><h2>Institutional Trading of Cognition Therapeutics</h2><p>A number of large investors have recently made changes to their positions in CGTX. DAVENPORT &amp; Co LLC purchased a new stake in shares of  Cognition Therapeutics during the third quarter worth about $3,631,000.  Vanguard Group Inc. grew its stake in  Cognition Therapeutics by 105.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,681,613 shares of the company's stock worth $3,620,000 after acquiring an additional 1,377,263 shares during the period.  Acadian Asset Management LLC raised its holdings in  Cognition Therapeutics by 814.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company's stock valued at $422,000 after acquiring an additional 897,353 shares during the last quarter.  Chescapmanager LLC lifted its stake in shares of  Cognition Therapeutics by 98.1% during the 3rd quarter. Chescapmanager LLC now owns 997,029 shares of the company's stock worth $1,346,000 after purchasing an additional 493,770 shares during the period.  Finally, Millennium Management LLC acquired a new stake in shares of  Cognition Therapeutics during the third quarter worth $757,000. Institutional investors and hedge funds own  43.35% of the company's stock. </p><h2>About Cognition Therapeutics</h2> (Get Free Report)<p>Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Cognition Therapeutics</li><li>3 Natural Gas Stocks That Offer Great Dividend Yields</li><li>MP Materials Stock Soared After Earnings—Here’s the Real Reason</li><li>Why Invest in High-Yield Dividend Stocks?</li><li>Why Palantir Slide May Be a Setup for a Long-Term Opportunity</li><li>ESG Stocks, What Investors Should Know</li><li>Attention Income Investors: This REIT Is on Sale</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cognition Therapeutics Right Now?</h2><p>Before you consider Cognition Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cognition Therapeutics wasn't on the list.</p><p>While Cognition Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CGTX

<p>Cognition Therapeutics, Inc. (NASDAQ:CGTX) has received a consensus rating of "Moderate Buy" from five brokerages. The stock has one sell rating, three buy ratings, and one strong buy rating. The average twelve-month price target is $3.3333. Recent ratings include B. Riley's buy rating with a $3.00 target and Chardan Capital's buy rating with a $4.00 target. The stock is currently trading at $1.39. Institutional investors hold 43.35% of the company's stock.</p>

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts